INTRODUCTION
Previously, opportunistic fungal infections were most often seen in patients with hematological disorders, in those who had undergone extensive surgical procedures, and in those receiving high doses of corticosteroid, cytotoxic, or immunosuppressive therapy. Currently, a dramatic increase in fungal infections, particularly candidiasis and cryptococcosis, is being seen in patients with the acquired immunodeficiency syndrome (AIDS). When one considers these increasing groups of patients who are likely to acquire an opportunistic fungal infection, the situation presents a unique challenge to the clinician and laboratorian.
The clinician must be familiar with the variety of clinical manifestations that may occur with opportunistic fungal infections in the immunocompromised patient. Fever is often the first indication of infection; this may be followed by signs and symptoms which suggest involvement of a specific * Corresponding author. organ system. Pulmonary disease occurs in many patients; cough (may be nonproductive in patients with granulocytopenia), shortness of breath and chest pain along with physical signs of tachypnea and auscultatory findings (rhonchi or decreased breath signs), and abnormal laboratory findings (arterial hypoxemia, decreased diffusion capacity with pulmonary function tests) may be observed.
Opportunistic fungal infections of the skin or musculoskeletal system are usually associated with disseminated disease. Head and neck infections may be self-limited (i.e., oral candidiasis or thrush) or rapidly fatal (i.e., ocular or sinus infections which may spread to involve the brain). Gastrointestinal infections most often involve the esophagus and rarely the small bowel and colon. Cardiovascular disease is usually the result of disseminated infection. Genitourinary disease may result from disseminated disease (renal parenchymal disease) or chronic indwelling urinary catheters (cystitis and pyelonephritis). Central nervous system infections may occur as a result of dissemination or direct extension from infected facial sinuses. Specific fungal pathogens are known to be associated with specific case scenarios. Granulocytopenia has a significant association with many fungi, especially Aspergillus species. Sinus infections caused by the zygomycetes are often associated with diabetic ketoacidosis. Certain dimorphic fungi are associated with opportunistic infections, particularly in those patients who have resided or visited in areas where the organisms, i.e., Coccidioides immitis, Histoplasma capsulatum, and Blastomyces dermatitidis, are ubiquitous. In addition, patients having granulocytopenia and those having lymphoproliferative disorders or lymphocyte dysfunction or quantitative depletion (AIDS) are subject to the acquisition of opportunistic fungal infections. Patients who present with opportunistic fungal infections and who are not known to be immunocompromised might have an immunologic investigation to include testing for antibodies to human immunodeficiency virus (HIV), the causative agent of AIDS.
The clinician must submit appropriate specimens to the laboratory to confirm and, in many instances, make the diagnosis of opportunistic fungal infection. Most often stains and cultures of tissue biopsies are necessary to establish a primary diagnosis. Blood cultures should be performed on all patients since this source may most rapidly detect the etiologic agent(s) of disseminated disease. Other body fluids including urine, cerebrospinal fluid, pleural fluid, peritoneal fluid, and synovial fluid, should be submitted for culture if the clinical signs and symptoms suggest infection of these sources (Table 1 ). In addition, appropriate fungal serologic tests may be helpful in making the diagnosis.
The clinical microbiology laboratory should provide and have experience with methods used for the rapid detection and identification of the fungi associated with infections of the immunocompromised patient. In addition, good communication between the laboratorian and clinician must exist to ensure prompt reporting and interpretation of results.
General Discussion of Laboratory Methods
Measures useful for the rapid detection and identification of fungi include microscopic demonstration of fungal elements in a clinical specimen, detection of fungal (cryptococcal) antigens, when appropriate, and recovery of the etiologic agent by using suitable culture media, along with rapid screening and confirmatory testing for the identification of an etiologic agent.
Perhaps the most rapid and useful of the methods available is the microscopic detection of fungal elements in clinical specimens. It is of interest to note that this may be accomplished in laboratories other than microbiology, such as the hematology or cytology laboratory (Table 2) . Therefore Chronic Mucocutaneous Candidiasis A specific complex presentation of Candida infection of the skin, mucous membranes, hair, and nails occurring in patients with an acquired T-lymphocyte deficit has been described. Specifically, T lymphocytes (thymus derived) do not respond with lymphocyte transformation or synthesis of macrophage inhibition factor after presentation with Candida antigen in vitro (116) . The clinical manifestations occur in infancy. Mucocutaneous candidiasis (onychomycosis and oral candidiasis) may also occur in other lymphocyte-deficient states, including HIV infection and endocrine disorders such as hypoparathyroidism and adrenal insufficiency. Cultures of scrapings from mucosa or skin lesions will result in the recovery of Candida species. The condition responds well to long-term -ketoconazole therapy (100).
Oral Candidiasis
In oral candidiasis or thrush, a white pseudomembranous patch forms on the tongue and other oral mucosal surfaces. Oral candidiasis occurs with HIV infection and other Tlymphocyte deficiency states, as well as with use of broadspectrum antimicrobial agents or inhaled steroid use by asthmatics. In patients with HIV infection, the presence of unexplained oral candidiasis predicts the development of serious opportunistic infections more than 50% of the time (68, 123) . The condition may be treated with oral nystatin, oral ketoconazole, or clotrimazole troches. The infection may be particularly recalcitrant in patients with HIV infection. Oral candidiasis may be associated with esophageal candidiasis, especially in patients with AIDS. Scrapings of the lesions will show pseudohyphae or yeast forms or both on KOH or Gram stain examination. Cultures of the lesion will also recover the etiologic agent.
Epiglottitis
Recently, several reports implicated Candida spp. as a cause of epiglottitis in immunocompromised patients. Candida epiglottitis may be underdiagnosed and should be considered in immunocompromised patients with pharyngeal complaints, including severe pain and odynophagia. Candida epiglottitis may occur as a localized infection, as a source of Candida bronchopneumonia, or as a manifestation of disseminated candidiasis. Diagnosis is achieved via cultures and microscopic examination of infected material collected by biopsy or scraping via direct visualization of the epiglottis. Treatment is with intravenous amphotericin B, and prompt endotracheal intubation may be necessary if the airway patency cannot be maintained (21, 23, 135) . localized involvement of the esophagus may be present (35) . Histopathologic examination will reveal the yeast or pseudohyphal form or both, and culture of the lesion will recover Candida spp. Treatment consists of either oral ketoconazole or oral clotrimazole, intravenous miconazole, or intravenous amphotericin B alone or in combination with oral flucytosine (5FC). The latter therapy is recommended in particularly severe cases. In patients with AIDS, the infection may be recurrent; moreover, instances of Candida esophagitis not responding to ketoconazole therapy have been reported in this population (124) .
Other Gastrointestinal Infections Species of Candida may also produce lesions in the remainder of the gastrointestinal tract. As with esophageal infection, Candida spp. can produce plaques or ulcerations in the stomach, small bowel, or colon. Endoscopic biopsy is the method of diagnosis, and treatment is often amphotericin B alone or in combination with SFC. Recently, focal granulomatous hepatitis due to Candida albicans has been observed in immunosuppressed patients, especially those with acute leukemia. Prominent gastrointestinal symptoms and signs along with elevated levels of alkaline phosphatase have been noted. In addition, computerized axial tomographic scans have shown hepatic defects with or without accompanying splenic defects. Often the infection is localized to the liver without evidence of dissemination. Microscopic preparations of liver biopsy material will reveal small numbers of yeast or pseudohyphal forms or both; however, cultures may be negative (52, 60, 122) . Species of Candida may also cause focal abscesses in the liver and spleen as well as in the abdominal peritoneal cavity.
Genitourinary Infection Candida infections in both immunocompetent and immunocompromised patients may involve the genitourinary tract (Candida cystitis and pyelonephritis particularly in patients with chronic indwelling urinary catheters), the vagina (vaginitis), and the extragenital areas (cutaneous candidiasis). Candida vaginitis may be particularly difficult to treat due to frequent recurrences in women infected with HIV (95) .
Candida cystitis is diagnosed by histopathologic examination and culture of the biopsied bladder tissue. Cystoscopy with retrograde ureteral studies may demonstrate fungus balls if present. The diagnosis of Candida pyelonephritis is more difficult; however, in the presence of recurrent funguria and azotemia, the diagnosis should be considered. Renal parenchymal abscesses may occur with disseminated infection.
The treatment for Candida cystitis is amphotericin B (by instillation into the bladder or systemically or both) and/or oral 5FC. The use of 5FC alone, however, may result in the emergence of resistant organisms. Treatment (126) . Other organ systems involved with disseminated candidiasis include the heart (myocarditis [37] , endocarditis [22] , and pericarditis [43] ), the lungs (often not a true pneumonitis but septic pulmonary emboli with microabscess formation [84] ), integument (macronodular erythematous or pink lesions and occasionally necrotic lesions resembling ecthyma gangrenosum), central nervous system tissue (meningitis and cerebral abscess [36, 110] ), and musculoskeletal system (arthritis [34] , osteomyelitis [107] , costochondritis [31] , and myositis [6] ). Disseminated disease may also result in infection of the peritoneum, liver, spleen, and gallbladder.
Diagnosis is achieved by blood cultures, biopsy, and cultures of other clinical specimens. Treatment is with amphotericin B with or without SFC. Some species of Candida exhibit in vitro resistance to 5FC and susceptibility testing should be performed whenever this drug is used (67) .
Laboratory Diagnosis
Candida albicans and other species of Candida are easily recognized by their characteristic microscopic morphologic features whether in culture, a clinical specimen, or tissue. Blastoconidia (budding yeast cells) 2 to 4 ,um in diameter or pseudohyphae with regular points of constriction or both can be seen by direct microscopic examination of clinical specimens, using phase-contrast microscopy or Calcofluor white staining ( Table 2 ). The organism is strongly gram positive and is easily recognized in specimens such as urine, vaginal secretions, and respiratory tract secretions. After growth appears in culture, Candida albicans may be identified by its ability to produce germ tubes or chlamydospores ( Since yeasts are the most common etiologic agents of fungemia, it is necessary that laboratories have the capability to detect their presence in blood. The Isolator (E. I. du Pont de Nemours), a lysis-centrifugation method, is considered by many to be the optimal fungal blood culture system. It has been shown to be more sensitive and rapid for the detection of yeasts and filamentous fungi than other systems, particularly a biphasic brain heart infusion medium (14) . Most yeasts are detected within 24 to 48 h of incubation. Some laboratories prefer to use the BACTEC radiometric system (Johnston Laboratories, Inc., Towson, Md.) since it is in common usage for the detection of bacteremia. Regardless of which system is used, fungal blood cultures should be offered to facilitate a diagnosis of fungemia in the immunocompromised patient.
Methods used for the detection of antibodies to Candida species include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, counterimmunoelectrophoresis, immunoelectrophoresis, double immunodiffusion in gel, and immunofluorescence. However, since immunocompromised patients are often unable to produce antibodies, there is a lower sensitivity of detection in this patient group than in the immunocompetent patient. These tests also lack specificity in distinguishing between colonization and deepseated invasion (25, 65) . Because of this insensitivity, tests for the detection of circulating Candida antigen and metabolites have been developed. The Candida Detection System, CAND-TEC (Ramco Laboratories, Inc., Houston, Tex.), is a latex agglutination test for the detection of circulating Candida protein antigens. In one study the system was evaluated for its ability to distinguish between patients with deep-seated candidiasis and those colonized with Candida albicans (40) . Results showed that the test may be useful in differentiating the two groups of patients, even among those who are immunocompromised. Another study of latex agglutination tests for circulating Candida antigens showed that they may be useful for diagnosing invasive candidiasis, but the transient nature of antigenemia requires frequent testing of patients' sera, which limits their usefulness (63) . Finally, metabolites of Candida spp. such as mannose and arabinitol have been detected in serum by gas-liquid chromatography. One study showed that patients with proven invasive candidiasis have elevated serum arabinitol levels and arabinitol/creatinine ratios compared with control patients without invasive candidiasis (47) . Commercially available kits for the detection of Candida antigens include the LA-Candida Antigen Detection System (Immuno-Mycologics, Inc., Washington, Okla.) for detection of circulating mannan antigen and the Candida Detection System (CAND-TEC).
Currently, the serologic diagnosis of candidiasis is complicated by the presence of a large, ever-growing number of reports of new tests that are proposed to be useful. Most have not been compared with already existing methods, and many are impractical to use or are generally unavailable except to the developer. We think that the serologic diagnosis of candidiasis is generally unhelpful at this time but predict that this will change in the near future. The aspergilli are frequently recovered in cultures of respiratory tract secretions, skin scrapings, and other specimens, which makes an assessment of their significance difficult. Repeated recovery of an organism from the same site or its recovery from several different sites may serve as evidence for infection, especially in the neutropenic patient (2, 128) .
Clinical Manifestations
In the immunocompromised host, Aspergillus spp. commonly produce an acute pneumonia which is usually fatal. Patients with acute leukemia, those receiving high-dose corticosteroid or cytotoxic drug therapy or both, or those who have recently undergone bone marrow transplantation with functional or absolute neutropenia are most often afflicted. Local invasive disease may occur in immunocompromised patients and has been reported rarely in immunocompetent hosts (18) .
Typically, a patient develops fever followed by pulmonary infiltrates with areas of consolidation on chest X ray. With time the lungs become more extensively involved, with an increase in infiltrates, even while the patient may be receiving amphotericin B therapy. Several authors have observed a "halo sign" (a halo of low attenuation appearing around masslike infiltrates). While this sign may not be pathognomonic for aspergillosis, its presence on tomograms or computerized axial tomographic scans of the lungs in the appropriate host may suggest early invasive aspergillosis (39, 73, 109) .
Often Aspergillus spp. disseminate from the lungs (114) to the brain (143), liver, kidneys, heart (55, 134), skin (48) , and rarely to the gastrointestinal tract (50, 90, 138) . Localized infection may also occur in the immunocompromised host, especially in the facial sinuses (131), often with contiguous spread to the brain to produce rhinocerebral aspergillosis (143) . Disseminated aspergillosis most often occurs in patients with granulocytopenia (44) .
Treatment for local disease is extensive surgical debridement and amphotericin B therapy; in pulmonary and disseminated disease, early treatment with amphotericin B is essential (2). There is debate as to whether the use of rifampin or 5FC in combination with amphotericin B is beneficial. Nevertheless, despite therapy, the prognosis is poor and the infection is usually fatal.
Laboratory Diagnosis
The diagnosis of aspergillosis is achieved by microscopic examination and culture of infected tissue. Tissue invasion is prominent, with obvious vascular invasion and subsequent tissue infarction. Aspergilli appear as hyaline, septate hyphae that exhibit dichotomous branching at 450 angles (Table  3) . A. flavus may be confused with zygomycetes (Rhizopus and Mucor spp.) since some isolates have large, sparsely septate hyphae.
Cultures of respiratory tract secretions commonly reveal Aspergillus spp., and their significance must be determined based on the clinical correlation. Venous blood cultures are not useful; however, it has been suggested that arterial blood cultures may be used to recover the organism. Most species of Aspergillus are partially or totally susceptible to cycloheximide; therefore, the battery of fungal culture media used should include at least one medium lacking this ingredient. However, when recovered, species of Aspergillus grow rapidly and produce mature colonies within 7 days. Identification of distinct species is based on the colonial and microscopic morphologic features (Table 3 ).
An early diagnosis of aspergillosis is difficult to make. Serologic methods to detect antibodies are usually not helpful since the humoral response in the immunocompromised patient may be variable or absent (103) . Therefore, attempts have been made to develop methods to detect soluble antigens of Aspergillus spp. in the serum, urine, or other body fluids to provide a rapid and specific diagnosis (27) . Tests that have been developed include radioimmunoassay (121) and ELISA (103) . However, none are commercially available for routine use in a clinical laboratory.
An inhibition ELISA capable of detecting 10 ng of Aspergillus carbohydrate antigen per ml in serum was developed which, in a retrospective study, detected antigen in the sera of 11 of 19 patients with invasive aspergillosis (103) . None of 14 healthy controls or 28 patients with a variety of other infections had antigen in their serum. Purified galactomannan from A. fumigatus has been used in both a radioimmunoassay and an ELISA for the detection of antigen in serum and urine (27) . The detection of galactomannan in the urine appeared to be a more sensitive test than serum antigen detection. Urinary antigen excretion roughly paralleled extent of disease. Other investigators (121) (Table 3) . Some confusion has been noted in trying to distinguish A. flavus from a zygomycete; however, the former usually appears to be somewhat more septate. Histopathologic examination of tissue, using hematoxylin-eosin stain, reveals the same morphologic features previously discussed. Methenamine silver usually fails to stain the hyphal elements well and is of little help in detecting the organism in many cases. However, an organism that stains well with hematoxylin-eosin but fails to stain with methenamine silver is suggestive of a zygomycete.
Cultures of respiratory tract secretions commonly contain zygomycetes; therefore, careful review of the clinical picture of the patient must be made to assess the significance of a positive culture. Specimen sources useful for the recovery of the etiologic agent of zygomycosis are presented in Table 1 .
In culture, the zygomycetes grow rapidly, within 1 to 2 days, and produce fluffy, white to grey to brown hyphal growth. Species of Mucor and Rhizopus grow as rapidly in vivo as in culture. Genera cannot be separated by their colonial morphologic features but must be distinguished by their microscopic morphologic characteristics (Table 3 ). All have large ribbonlike hyphae that are irregular in diameter and are sparsely or occasionally septate. Specific identification is confirmed by observing characteristic sporangia at the tips of sporangiophores, presence or absence of rhizoids, and the position of the rhizoids in relation to the sporangiophores.
Diagnostic serologic tests are not available for use in the clinical laboratory. One report, however, describes a case of systemic zygomycosis diagnosed by percutaneous needle aspiration of a perinephric abscess and confirmed with an enzyme immunoassay that detected humoral antibodies (75) . The rapid detection of an organism in a clinical specimen by direct microscopic examination or culture is currently the most important means of making a diagnosis of this important infection.
CRYPTOCOCCOSIS
Cryptococcosis, primarily an infection of the immunocompromised host, is produced by Cryptococcus neoformans, a member of the class Basidiomycotina, the group to which the mushrooms belong. The organism is widely distributed in nature and is most often found in association with the excreta of pigeons. It is thought that exposure to Cryptococcus neoformans is common and that the primary route of entry is by inhalation. However, a history of exposure is difficult to obtain from patients, and activities associated with aerosol production are most often lacking. In addition, the number of recognized cases of pulmonary cryptococcosis are few when compared with cases of disseminated infection or meningitis; perhaps many are self-resolving.
Since cryptococcosis most often occurs in the immunocompromised host, its presence in any specimen should be considered significant until proven otherwise. However, a recent review of our patient records at Mayo Clinic from 1975 to 1984 showed >100 cases of colonization of the respiratory tract without subsequent development of infection within 6 years of patient follow-up. However, none of the patients were immunocompromised. Therefore, it is necessary to rule out infection in patients from whom
Cryptococcus neoformans is recovered to ensure a proper diagnosis.
Central Nervous System Infection-Meningitis A frequent presentation of cryptococcosis involves the central nervous system in the form of meningitis. The onset is insidious, with decreasing hearing, impaired cognitive function, headache, fatigue, drowsiness, irritability, and clumsiness often preceding overt clinical signs involving cranial nerve dysfunction and meningismus. The gradual onset of the illness and lack of specific signs and symptoms in early disease are likely a result of a minimal inflammatory reaction in tissues. In AIDS patients, large numbers of organisms may be present in tissue, with a striking paucity of an inflammatory response (41, 101) .
Remarkably, some patients with cryptococcal meningitis have no specific immune deficit preceding their illness. Others may be receiving high-dose corticosteroid therapy or have lymphoproliferative disorders, especially lymphoma, sarcoidosis, or HIV infection (32, 72, 147) or diabetes mellitus. Interestingly, in many patients receiving high doses of corticosteroids, the signs and symptoms of meningitis are often suppressed. Cryptococcal central nervous system infection should be suspected in patients receiving corticosteroid therapy since this association has been well documented.
Treatment may be with amphotericin B alone or in combination with 5FC. In non-AIDS patients, the latter treatment regimens result in a cure rate similar to that with amphotericin B alone, but toxicity is less (11) . In AIDS patients, continuation of suppressive antifungal therapy is usually necessary. Recently, fluconazole, a triazole compound, has been shown to be of use in the treatment of cryptococcal infection in AIDS patients who have not responded to amphotericin B and 5FC therapy (19) .
Infection of the Respiratory Tract and Other Sites As previously mentioned, Cryptococcus neoformans may be recovered from patients having only pulmonary colonization. This, in conjunction with the relatively few reported cases of pulmonary cryptococcosis, makes the clinical diagnosis of this entity somewhat difficult in patients with or without chest roentgenogram abnormalities. Pulmonary cryptococcosis may occur in both immunocompromised and immunocompetent hosts. Many cases of pulmonary infection resolve without treatment in the latter, but disseminated infection commonly occurs in the abnormal host unless antifungal therapy is administered.
Other sites that may be involved include the skin and bone and, rarely, the kidneys, liver, and genitourinary tract. Blood cultures may be positive for Cryptococcus neoformans in afebrile patients who are immunosuppressed, without an identifiable source of infection. In many of these patients the organism can be found in respiratory tract secretions or cerebrospinal fluid. Cryptococcosis is the most common disseminated fungal infection seen in patients with AIDS. Unusual cases of myocarditis (76), cutaneous infection resembling molluscum contagiosum (97) , arthritis (96) , and prostatitis (79) The direct microscopic examination of cerebrospinal fluid for the detection of Cryptococcus neoformans has been traditionally associated with the India ink preparation. It is commonly used in clinical laboratories, but has a low sensitivity and detects <40% of culture-proven cases of cryptococcal meningitis (Table 2) . We recommend that it not be used in the clinical laboratory but rather be replaced by the cryptococcal latex test for antigen. The latex test detects the presence of solubilized capsular polysaccharide antigen in serum and cerebrospinal fluid. The test is sensitive and detects as many as 99% of patients having meningitis (66) . A small number of false-positive tests occur due to rheumatoid factor or other interference factors, but a simple method to eliminate these factors has been developed (117) . A portion of the serum or cerebrospinal fluid is treated with a protease (pronase), heat inactivated, and tested. False-positive results are eliminated, and in many instances titers are higher after treatment due to the disassociation of antigen-antibody complexes. This treatment appears to enhance the sensitivity of the test by detecting antigen previously bound by antibody. Cryptococcal antigen may be detected in the serum of approximately 66% of patients having disseminated infection and only a few (<10%) with pulmonary infection (28) .
Direct microscopic detection of Cryptococcus neoformans in specimens other than cerebrospinal fluid is also easily accomplished. Cryptococcus neoformans appears as a spherical, single, or multiply budding yeast. Extreme variation in the size of cells (2 to 15 ,um) is apparent, and although the organism is described as being encapsulated, not all isolates produce the polysaccharide capsule (Table 3) . Calcofluor white staining or phase-contrast microscopy makes it easier to detect this organism in clinical specimens. The methenamine silver stain is optimal for detection of Cryptococcus neoformans in tissue.
Recovery of Cryptococcus neoformans in culture is easily accomplished by using most routine fungal culture media without cycloheximide. Yeastlike colonies (dry or mucoid) appear within 1 to 5 days, and pigmentation varies depending on the medium used for culture. After growth appears, a presumptive identification may be made based on urease production, lack of nitrate reductase, and presence of phenol oxidase. The definitive identification is based on carbohydrate utilization profiles and pigment production on niger seed agar (Table 3) .
TRICHOSPORONOSIS
Species of Trichosporon are widely distributed in nature and may also be found in respiratory secretions, stool, and urine (53) and on the skin of healthy persons. Trichosporon beigeifi (T. cutaneum), the most common cause of trichosporonosis, has long been recognized as the etiologic agent of white piedra, an infection of the hair of persons living in tropical and temperate parts of the world.
Trichosporonosis, as an infection of the immunocompromised host, has been recognized only during the past 17 years. Of the 42 cases of disseminated infection recognized, 27 (64%) were reported during 1986 to 1987.
Disseminated infection is seen primarily in patients with hematologic malignancy and profound neutropenia (57) . However, infection has been found in patients undergoing renal (53) and bone marrow (57) transplantation, prosthetic valve surgery (94) , or hepatitis (71) .
Clinical Manifestations
The clinical manifestations of trichosporonosis are diverse and the diagnosis is usually not suspected. Many patients present with signs and symptoms that suggest disseminated candidiasis (6) . Purpuric skin lesions are common, and most VOL. 1, 1988 progress to produce large areas of necrosis (46, 144) and deep-tissue involvement (5, 7, 77, 82, 133) . In some instances an oral infection resembling thrush may be seen (92) , pneumonia is common (69, 106) , and hepatitis (71) may occur. Significant mortality has been associated with disseminated infection.
In vitro studies have shown the organism to be susceptible to amphotericin B, ketoconazole, and miconazole. Large clinical studies are lacking regarding the appropriate treatment, although case reports have suggested that amphotericin B alone or in combination with 5FC may be useful (12, 136) .
Laboratory Diagnosis
The diagnosis of trichosporonosis is made most often by the recovery of T. beigelii from blood, skin lesions, or other tissue obtained at autopsy. The organism grows well on all commonly used fungal culture media and forms smooth, shiny colonies within 1 week of incubation which later become membranous, dry, and cerebriform (Table 3) . Identification is based on the presence of hyphae with arthroconidia and blastoconidia produced on cornmeal agar. Biochemically, T. beigelii does not ferment carbohydrates and produces urease and a characteristic carbohydrate utilization profile.
The diagnosis may also be made based on recognition of the organism in tissue by observing hyphae with numerous arthroconidia and a few blastoconidia (Table 3) . Lesions are typically composed of radially arranged hyphae with or without central necrosis (77) . In some instances, blastoconidia are absent, and the differential diagnosis will include trichosporonosis or geotrichosis since the etiologic agents of both produce arthroconidia.
T. beigelii produces a heat-stable antigen which shares antigenic determinants with the capsular polysaccharide of Cryptococcus neoformans. The latex test for cryptococcal antigen has been reported to be positive when serum of patients having disseminated trichosporonosis has been tested (87, 88) . Detection of antigenemia may correlate with invasive disease in patients whose surveillance cultures of skin, sputum, stool, or urine become positive with T. beigelii. In this situation, the cryptococcal latex test for antigen might suggest infection with Trichosporon spp. before identification of the culture is made. PSEUDALLESCHERIASIS P. boydii, the organism most commonly recognized as the major etiologic agent of mycetoma in North America, is being seen with greater frequency as the cause of a number of different clinical entities. The organism is widely distributed in nature and has been recovered from soil, poultry, cattle manure, polluted streams, brackish water, and coastal waters. It is common to recover P. boydii from respiratory tract secretions and gastric washings of healthy persons; however, its presence deserves serious consideration as a potential pathogen.
Clinical Manifestations
Recognition of P. boydii as a cause of infection in the immunocompromised host is becoming increasingly important. Pulmonary disease with massive intra-alveolar hemorrhages, congestion, mycotic thrombi, and multiple fungal lesions has been noted. Local disease may occur in the paranasal sinuses which may then extend into the orbit and meninges (45, 54) . In addition, disseminated infection with involvement of deep viscera including the thyroid, kidneys, brain, and heart has been described (33, 108, 111) . Cases of brain abscess are being reported more often (127, 142) . Tricuspid valve endocarditis reported in a patient receiving corticosteroid therapy apparently evolved as a result of an implanted pacemaker which became infected with P. boydii (24) . Fungal sinusitis in both immunocompetent and immunocompromised patients is becoming more prevalent.
Pseudallescheriasis presents a serious threat to the immunocompromised patient by its potentially pathogenic nature, but more importantly, from a therapeutic standpoint: little success has been achieved in the treatment of this infection. Surgical debridement, when appropriate, in combination with intravenous amphotericin B has been used with varying degrees of success. Miconazole now appears to be the recommended treatment of choice; however, ketoconazole has been used in a limited number of cases (42, 81) . Early diagnosis and rapid treatment appear to increase the chances of a favorable outcome.
Laboratory Diagnosis
The definitive laboratory diagnosis of pseudallescheriasis depends on the recovery and identification of P. boydii from clinical specimens. The organism is easily recovered from tissue, blood, and other sources within 5 days of incubation. Colonies are initially white and fluffy but soon become mousey grey with a dark black to brown reverse. The asexual form of P. boydii (Scedosporium apiospermum) produces elliptical to elongated, single-celled conidia borne singly from the tips of long or short conidiophores (annellophores). Some cultures produce the Graphium state in which clusters of conidiophores producing conidia at their tips appear to be cemented together (synnemata). The sexual form exhibits cleistothecia (50 to 200 pm) which contain asci and ascospores (Table 3) . According to taxonomists, one should report the organism as S. apiospermum when the asexual form is seen and P. boydii when the sexual form is found. Clinical laboratories can make their own decision as to what name should be used for reporting the results to clinicians.
P. boydii may be seen in tissue as small hyphae which may or may not exhibit dichotomous branching. Microscopically, this organism cannot be distinguished from Aspergillus spp. or other fungi (Table 3) .
FUSARIUM INFECTION
The genus Fusarium contains nine species, all of which are plant pathogens and widely distributed in nature. Only a few species have been incriminated as causes of human infection, keratomycosis being the most common. However, during the past few years, an increasing number of different infections have been reported in the immunocompromised host. Fusarium solani has been shown to cause disseminated infection with fungemia (3, 4, 20, 85, 91, 129) . Fusarium moniliforme and Fusarium proliferatum have been associated with pneumonia and disseminated infection in patients with leukemia (61, 120, 145) . Infection with Fusarium spp. has also been seen in patients undergoing bone marrow transplantation (15, 91) .
Most infections have been fatal, but amphotericin B therapy has been of benefit in a few cases. The definitive diagnosis of Fusarium infection is made by recovering and identifying the organism from a patient who has a compatible clinical history or histopathologic evidence of infection or both. Fusarium spp. cannot be distinguished from Aspergillus spp., P. boydii, or other fungi by microscopic examination of tissue sections. The definitive diagnosis depends on identification of the genus and species involved. The genus is easily recognized by observing hyphae having single phialides which produce either single-celled oval microconidia or, more commonly, gelatinous heads of large sickle-shaped septate macroconidia. Some cultures produce chlamydospores which aid in their identification ( Table 3) .
Colonies of Fusarium spp. may appear in many colors, including pink, purple, yellow, and green, and are fluffy to cottony in texture. Colonial morphology, however, plays little role in the final identification of the organism.
OTHER UNCOMMON FUNGAL INFECTIONS
The immunocompromised host is susceptible to any microorganism if host responses are diminished and other factors are impaired. This is evident by the number of infections reported that have been caused by organisms not usually known to be pathogenic under ordinary circumstances.
A variety of fungi other than those discussed in this review have been recognized as causing infection in the immunocompromised host; only a few examples are included in this discussion. Paecilomyces lilacinum has been associated with cellulitis in an immunosuppressed patient (59) . Cutaneous infections have also been reported to be caused by Exophiala jeanselmei (cutaneous nodules) (146), Malassezia furfur (folliculitis) (141), Alternaria species (cutaneous nodular lesions) (132) , and Penicillium species (generalized subcutaneous abscesses) (112) . Other infections reported include Aureobasidium pullulans (splenic and disseminated infection) (62, 104) , Rhodotorula species (disseminated infection) (102) , Chaetomium species (empyema) (56), Torulopsis candida (fungemia) (115) , Curvularia species (nasopharnygeal infection) (80), Cunninghamella species (pneumonia) (130) , Geotrichum candidum (disseminated infection) (64) , and members of the dematiaceous fungi including Drechslera, Bipolaris, and Exserohilum (1, 26, 38, 86, 98) .
To this partial list can be added the dimorphic pathogens H. capsulatum, B. dermatitidis, Coccidioides immitis, Sporothrix schenckii, and Paracoccidioides brasiliensis. In the past these infections have been associated with the immunocompetent host, but now they are being increasingly recognized in the immunocompromised hosts, including those with leukemia and AIDS and patients receiving longterm corticosteroid therapy (13, 16, 17, 83, 118, 139, 140) . The intent of this review is to make the reader aware that fungal infections of the immunocompromised patient are becoming much more common and that any organism should be considered a potential etiologic agent. This requires that the clinical microbiology laboratory thoroughly identify and report all fungi found in clinical specimens from such patients. By doing this, the clinician may assess the clinical significance of a fungal isolate. It is reasonable to expect that opportunistic fungal infections will be seen with increasing frequency, and the clinical laboratory should be prepared to identify fungi that are infrequently encountered on a daily basis. 
